Abstract 1278P
Background
The first interim analysis of the phase 3 INSPIRE study (NCT04632758) (data cutoff: Nov 13, 2022) showed that iruplinalkib significantly improved PFS versus crizotinib in patients (pts) with advanced ALK+ and ALK TKI-naïve NSCLC. Here we present updated survival and safety results after additional follow-up.
Methods
Pts with ALK+, stage IIIB/IV NSCLC naïve to ALK TKI were randomized (1:1) to oral iruplinalkib 180 mg QD (7-day run-in at 60 mg QD) or crizotinib 250 mg BID. The primary endpoint was PFS assessed by Independent Review Committee (IRC) per the RECIST version 1.1. Secondary endpoints included PFS by investigator (INV), OS and safety.
Results
From Sep 4, 2019 to Dec 2, 2020, 292 pts were randomized (iruplinalkib/crizotinib, n=143/149). The data cutoff date of this updated analysis was Oct 25, 2023. Median follow-up for PFS by IRC was 35.02 months for iruplinalkib and 34.96 months for crizotinib. Median PFS by IRC was 36.80 months for iruplinalkib and 14.55 months for crizotinib (HR, 0.311 [98.02% CI, 0.222-0.436]; stratified one-sided log-rank p<0.0001). Other efficacy results are presented in the table. Incidence of ≥ grade 3 treatment-related AEs was 53.1% for iruplinalkib and 51.0% for crizotinib.
Conclusions
These results demonstrated iruplinalkib continued to improve PFS versus crizotinib in pts with advanced ALK+ and ALK TKI-naïve NSCLC. The safety profile was consistent with prior results and no new safety findings was observed. Table: 1278P
Updated survival results of iruplinalkib versus crizotinib
| Iruplinalkib (n=143) | Crizotinib (n=149) | |
| mPFS by INV, mo (95% CI) | 31.11 (23.98-38.60) | 14.75 (11.10-16.56) |
| HR (95% CI) | 0.423 (0.312-0.573) | |
| mPFS in ALK+ pts by IRC, mo (95% CI) | 45.90 (28.32-NE) | 14.55 (11.07-16.53) |
| HR (95% CI) | 0.292 (0.199-0.430) | |
| mPFS in pts with baseline CNS metastases by IRC, mo (95% CI) | 26.25 (18.27-NE) | 11.01 (7.46-14.72) |
| HR (95% CI) | 0.215 (0.103-0.449) | |
| mPFS in pts without baseline CNS metastases by IRC, mo (95% CI) | 45.90 (29.50-NE) | 16.39 (12.88-18.30) |
| HR (95% CI) | 0.330 (0.222-0.489) | |
| 36-mo OS rate (%) (95% CI) | 81.3 (73.8-86.9) | 75.8 (67.8-82.1) |
Note: ALK+ pts were those whose ALK status was confirmed positive by both central laboratory and local hospitals.
Clinical trial identification
NCT04632758.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
M. Si, H. Li, L. Li, X. Kang: Other, Personal, Full or part-time Employment: Qilu Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1334P - PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis
Presenter: Nikolaj Frost
Session: Poster session 05
1335P - The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC)
Presenter: Maaike Hofman
Session: Poster session 05
1338P - TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Fabrizio Citarella
Session: Poster session 05
1339P - Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC
Presenter: Utsav Joshi
Session: Poster session 05
1341P - Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study
Presenter: Yuki Katayama
Session: Poster session 05
1342P - The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status
Presenter: Walid Shalata
Session: Poster session 05
1343P - Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%
Presenter: Andrea De Giglio
Session: Poster session 05
1344P - Plasma proteomics indicated predictive biomarkers for immuno-chemotherapy in stage IIIB-IV non-small cell lung cancer without EGFR/ALK alterations
Presenter: Zhihuang Hu
Session: Poster session 05